ArticleThe Korean journal of chemical engineering2022
Epigenome editing and epigenetic gene regulation in disease phenotypes.
Article in The Korean journal of chemical engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- Advances and clinical potential of epigenome editing.Cellular and molecular life sciences : CMLS · 2026Review
- CRISPR-epigenetic crosstalk: From bidirectional regulation to therapeutic potential.Computational and structural biotechnology journal · 2025Review
- The epigenetic modification of DNA methylation in neurological diseases.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Proper gene control across space and time is crucial for the seamless execution of various cellular functions. Rapid advancements in genome-wide studies revealed that in addition to genetic mutations, epigenetic modifications also play an important role in cellular processes and disease development. Epigenetic modifications, including DNA methylation and post-translational modifications on histones via methylation, acetylation, phosphorylation, etc., do not alter DNA sequences. Yet, disruptions of the epigenome can still induce gene malfunction, aberrant cell differentiation, proliferation, and apoptosis, resulting in various diseases such as cancer, neurological disorders, and autoimmune diseases. This review describes the association between epigenetic modifications and disease phenotypes, current techniques to perturb epigenome and analyze changes in gene expression, and perspectives on future epigenetic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.